Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

E ven medical research isn’t immune to a federal overhaul. The life sciences have joined DEI efforts, climate laws and ...

and Cambridge. Moderna will rub shoulders there with the likes of the UK Health Security Agency (UKHSA), with which it is working on early vaccine development for future pandemic threats ...

Moderna has said it will open a new R&D and ... but could be in the 'golden triangle' that extends between London, Oxford and Cambridge and encompasses the UK's main biopharma cluster, or possibly ...

Etiome will use its Temporal Biodynamics platform to stage serious, progressive chronic diseases and develop targeted therapeutics.

As a result, Moderna's shares have suffered, falling more than 90% since their peak in 2021. Now let's consider where Moderna will be a few years from now. The company recently said it aims to ...

Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires ...

Moderna stock hasn’t been a favorite of investors since demand for its coronavirus vaccine started to drop. But this biotech is showing the market that it has what it takes to produce multiple ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies ...

A fire broke out at a caravan site in Cambridge on Sunday morning (April 20). The fire spread to 11 caravans, the stables, other buildings, and vehicles in the Fen Road area. Emergency services ...